XML 36 R23.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Selected Quarterly Financial Data (Unaudited) | 12 Months Ended
--- | ---
Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract] |
Selected Quarterly Financial Data (Unaudited) | Selected Quarterly Financial Data (Unaudited) Selected quarterly financial data for 2017 and 2016 are as follows:
| Three Months Ended
| March |  | June |  | September |  | December
2017 |  |  |  |  |  |  |
Net sales | $ | 186,567 |  |  | $ | 197,154 |  |  | $ | 190,117 |  |  | $ | 222,555 |
Gross profit | 99,885 |  |  | 104,652 |  |  | 102,547 |  |  | 123,958 |
Net income (loss) | (4,545 | ) |  | 6,139 |  |  | 7,197 |  |  | 46,696 |
EPS: |  |  |  |  |  |  |  |  |  |  |
Basic | $ | (.16 | ) |  | $ | .22 |  |  | $ | .26 |  |  | $ | 1.67 |
Diluted | (.16 | ) |  | .22 |  |  | .26 |  |  | 1.65 |
| Three Months Ended
| March |  | June |  | September |  | December
2016 |  |  |  |  |  |  |
Net sales | $ | 181,201 |  |  | $ | 193,433 |  |  | $ | 184,792 |  |  | $ | 204,094 |
Gross profit | 97,740 |  |  | 102,422 |  |  | 101,209 |  |  | 106,959 |
Net income (loss) | (2,265 | ) |  | 2,884 |  |  | 7,337 |  |  | 6,708 |
EPS: |  |  |  |  |  |  |  |  |  |  |
Basic | $ | (.08 | ) |  | $ | .10 |  |  | $ | .26 |  |  | $ | .24 |
Diluted | (.08 | ) |  | .10 |  |  | .26 |  |  | .24 |
Items Included In Selected Quarterly Financial Data: 2017 First Quarter During the first quarter of 2017, we incurred $1.2 million in costs associated with operational restructuring. These costs were charged to cost of sales and include severance and other charges - see Note 12. During the first quarter of 2017, we incurred $0.5 million in costs associated with the expensing of unvested options acquired and integration related costs associated with the acquisition of SurgiQuest, Inc. These costs were charged to selling and administrative expense - see Note 12. During the first quarter of 2017, we incurred $12.2 million in costs associated with the SurgiQuest, Inc. vs. Lexion Medical litigation verdict whereby SurgiQuest was found liable for $2.2 million in compensatory damages with an additional $10.0 million in punitive damages. These costs were charged to selling and administrative expense - see Notes 11 and 12. During the first quarter of 2017, we incurred $2.0 million in costs associated with a patent settlement, legal fees associated with the SurgiQuest, Inc. vs. Lexion Medical litigation and other legal matters. These costs were charged to selling and administrative expense - see Notes 11 and 12. During the first quarter of 2017, we restructured certain selling and administrative functions and incurred $1.3 million in related costs consisting principally of severance charges. These costs were charged to selling and administrative expense- see Note 12. Second Quarter During the second quarter of 2017, we incurred $0.3 million in costs associated with operational restructuring. These costs were charged to cost of sales and include severance and other charges - see Note 12. During the second quarter of 2017, we incurred $0.4 million in costs associated with the expensing of unvested options acquired and integration related costs associated with the acquisition of SurgiQuest, Inc. These costs were charged to selling and administrative expense - see Note 12. During the second quarter of 2017, we incurred $2.5 million in costs associated with SurgiQuest, Inc. vs. Lexion Medical litigation and other legal matters. These costs were charged to selling and administrative expense - see Notes 11 and 12. Third Quarter During the third quarter of 2017, we incurred $1.3 million in costs associated with operational restructuring. These costs were charged to cost of sales and include the write-off of inventory no longer being offered for sale and other charges - see Note 12. During the third quarter of 2017, we incurred $0.1 million in integration related costs associated with the acquisition of SurgiQuest, Inc. These costs were charged to selling and administrative expense - see Note 12. During the third quarter of 2017, we incurred $0.3 million in costs associated with SurgiQuest, Inc. vs. Lexion Medical litigation and other legal matters. These costs were charged to selling and administrative expense - see Notes 11 and 12. Fourth Quarter During the fourth quarter of 2017, we incurred $0.1 million in costs associated with operational restructuring. These costs were charged to cost of sales - see Note 12. During the fourth quarter of 2017, we incurred $1.3 million in integration related costs associated with the acquisition of SurgiQuest, Inc. These costs were charged to selling and administrative expense - see Note 12. During the fourth quarter of 2017, we incurred $0.4 million in costs associated with SurgiQuest, Inc. vs. Lexion Medical litigation and other legal matters. These costs were charged to selling and administrative expense - see Notes 11 and 12. During the fourth quarter of 2017, we recorded an income tax benefit of $31.9 million resulting from the 2017 Tax Cuts and Jobs Act - see Note 7. 2016 First Quarter During the first quarter of 2016, we incurred $0.9 million in costs associated with the consolidation of our Centennial, Colorado manufacturing operations into other existing CONMED manufacturing facilities. These costs were charged to cost of sales and include severance and other charges associated with the consolidation – see Note 12. During the first quarter of 2016, we incurred $8.2 million in costs associated with the January 4, 2016 acquisition of SurgiQuest, Inc. These costs include investment banking fees, consulting fees, legal fees associated with the acquisition, costs associated with expensing of unvested options acquired and integration related costs and were charged to selling and administrative expense - see Notes 2 and 12. During the first quarter of 2016, we incurred $0.8 million in costs associated with SurgiQuest, Inc. vs. Lexion Medical litigation. These costs were charged to selling and administrative expense - see Notes 11 and 12. During the first quarter of 2016, we incurred a $2.7 million charge related to commitment fees paid to certain of our lenders, which provided a financing commitment for the SurgiQuest acquisition and recorded a loss on the early extinguishment of debt of $0.3 million in conjunction with the fifth amended and restated senior credit agreement. These costs were charged to other expense - see Notes 6 and 12. During the first quarter of 2016, we recorded a charge of $2.8 million to selling and administrative expense related to the restructuring of certain selling and administrative functions which includes severance and other related costs - see Note 12. Second Quarter During the second quarter of 2016, we incurred $0.1 million in costs associated with the consolidation of our Centennial, Colorado manufacturing operations into other existing CONMED manufacturing facilities. These costs were charged to cost of sales and include severance and other charges associated with the consolidation – see Note 12. During the second quarter of 2016, the Company discontinued our Altrus product offering as part of our ongoing restructuring and incurred $4.5 million in non-cash charges which were included in cost of sales - see Note 12. During the second quarter of 2016, we incurred $3.6 million in costs associated with the acquisition of SurgiQuest, Inc. which include consulting fees, legal fees associated with the acquisition, costs associated with expensing of unvested options acquired and integration related costs. These costs were charged to selling and administrative expense - see Notes 2 and 12. During the second quarter of 2016, we incurred $1.4 million in costs associated with SurgiQuest, Inc. vs. Lexion Medical litigation and other legal matters. These costs were charged to selling and administrative expense - see Notes 11 and 12. During the second quarter of 2016, we recorded a charge of $1.0 million to selling and administrative expense related to the restructuring of certain selling and administrative functions which includes severance and other related costs - see Note 12. Third Quarter During the third quarter of 2016, we incurred $2.7 million in costs associated with the acquisition of SurgiQuest, Inc. which include consulting fees, legal fees associated with the acquisition, costs associated with expensing of unvested options acquired and integration related costs. These costs were charged to selling and administrative expense - see Notes 2 and 12. During the third quarter of 2016, we incurred $0.6 million in costs associated with SurgiQuest, Inc. vs. Lexion Medical litigation and other legal matters. These costs were charged to selling and administrative expense - see Notes 11 and 12. During the third quarter of 2016, we sold our Centennial, Colorado facility. We received net cash proceeds of $5.2 million and recorded a gain of $1.9 million on the sale of our facility in selling and administrative expense - see Note 12. During the third quarter of 2016, we recorded a charge of $0.4 million to selling and administrative expense related to the restructuring of certain selling and administrative functions which includes severance and other related costs - see Note 12. Fourth Quarter During the fourth quarter of 2016, we incurred $2.1 million in severance and other related costs associated with restructuring. These costs were charged to cost of sales - see Note 12. During the fourth quarter of 2016, we incurred $2.5 million in costs associated with the acquisition of SurgiQuest, Inc. which include consulting fees, legal fees associated with the acquisition, costs associated with expensing of unvested options acquired and integration related costs. These costs were charged to selling and administrative expense - see Notes 2 and 12. During the fourth quarter of 2016, we incurred $1.0 million in costs associated with SurgiQuest, Inc. vs. Lexion Medical litigation and other legal matters. These costs were charged to selling and administrative expense- see Notes 11 and 12. During the fourth quarter of 2016, we recorded a charge of $2.6 million to selling and administrative expense related to the restructuring of certain selling and administrative functions which includes severance and other related costs - see Note 12.

X
- References No definition available. + Details
Name: | us-gaap_QuarterlyFinancialInformationDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -URI http://asc.fasb.org/topic&trid=2126967 + Details
Name: | us-gaap_QuarterlyFinancialInformationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration